Table 3 APD prescription details
RT | CCRT | |||
|---|---|---|---|---|
Total patients prescribed APD | Patients prescribed APD during RT | Total patients prescribed APD | Patients prescribed APD during CCRT | |
APD prescription time | N = 107,984 | N = 41,118 | N = 24,623 | N = 8,129 |
Pre-RT | 28,085 (26.01%) | 12,655 (30.78%) | 5,262 (21.37%) | 2,061 (25.35%) |
During RT | 28,463 (26.36%) | 28,463 (69.22%) | 6,068 (24.64%) | 6,068 (74.65%) |
After RT | 51,436 (47.63%) | 16,329 (39.71%) | 13,293 (35.06%) | 2,990 (36.78%) |
60 ~ 365days | 21,725 (20.12%) | 10,979 (26.70%) | 6,146 (16.21%) | 2,201 (27.07%) |
> 365days | 29,711 (27.51%) | 5,350 (13.01%) | 7,147 (18.85%) | 789 (9.70%) |
APD duration | - | - | ||
Within 3 months | 36,511 (88.8%) | 7,542 (92.78%) | ||
Over 3months | 4,607 (11.2%) | 587 (7.22%) | ||
APD dose * | N = 86,808 | N = 38,108 | N = 19,806 | N = 7,742 |
Low dose | 79,168 (91.2%) | 36,140 (94.8%) | 17,984(90.8%) | 7,299 (94.3%) |
High dose | 7,830 (11.8%) | 1,968 (5.2%) | 1,822 (9.2%) | 443 (5.7%) |